
How is KISQALI dosed in early breast cancer?
For patients with stage II/III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) at high risk of recurrence, the starting dose for KISQALI® (ribociclib) is 400 mg (two 200-mg tablets) orally, once daily (3 weeks on, 1 week off), for 3 years, in combination with an aromatase inhibitor (AI). Learn about KISQALI dosing for eBC below.1
In stage II/III HR+/HER2- eBC,
The KISQALI 400-mg once-daily starting dose was chosen to reduce both the risk of recurrence and dose-dependent adverse reactions
(28-day cycle)1 | Week 1 | Week 2 | Week 3 | Week 4 | Subsequent cycles |
KISQALI: 2 | Repeat 28-day cycle | ||||
AI |
KISQALI is given as 400 mg (two 200-mg tablets) orally, once daily (3 weeks on, 1 week off) for 3 years with an AI1
Review the full Prescribing Information for recommended dosing of selected AI
An LHRH agonist should be used concomitantly with AI in men and premenopausal women
Patients should continue treatment for 3 years or until disease recurrence or unacceptable toxicity
KISQALI can be taken with or without food
Patients may store at room temperature at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)
Store in the original blister package in order to protect from moisture
Starting dose modification for severe renal impairment1
The recommended starting dose is 200 mg once daily for patients with severe renal impairment
AI, aromatase inhibitor; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinizing hormone-releasing hormone.



